Antiplatelet agents in acute coronary syndromes.
The platelet plays an essential role in atherothrombosis. Clinically, platelet-rich thrombi underlie acute coronary syndromes (ACSs). Current therapies have improved outcomes, however, often at the expense of increased risk of bleeding. With the increase in our understanding of the underlying pathophysiology of ACSs, newer targets for antiplatelet therapies continue to emerge. Novel antiplatelet agents may provide even greater reductions in ischemic events with the potential for less bleeding. This article reviews the evidence for current antiplatelet agents in ACSs as well as for the newer agents in later phases of clinical testing.
Rahul
R
Sakhuja
Robert W
RW
Yeh
Deepak L
DL
Bhatt
D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D004351:Drug Resistance; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D013997:Time Factors; D016896:Treatment Outcome
D015507:Drugs, Investigational; D010975:Platelet Aggregation Inhibitors